Asset Details
Do you wish to reserve the book?
Evaluation of Rift Valley fever vaccine candidates in pregnant rodent models
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evaluation of Rift Valley fever vaccine candidates in pregnant rodent models
Do you wish to request the book?
Evaluation of Rift Valley fever vaccine candidates in pregnant rodent models
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evaluation of Rift Valley fever vaccine candidates in pregnant rodent models
2026
Overview
Rift Valley fever virus (RVFV) causes significant disease in humans and livestock. Immunogenicity of candidate vaccines rMP-12 and RVax-1 show promise, but their placental tropism and potential effects on fetal outcomes remain incompletely understood, particularly across different animal models. Understanding species-specific placental replication is essential to optimize vaccine safety in pregnant populations.
To evaluate the placental tropism and fetal outcomes of RVFV candidate vaccines rMP-12 and RVax-1 in pregnant Sprague–Dawley (SD) rats and C57BL/6 mice.
Pregnant SD rats and C57BL/6 mice were vaccinated intramuscularly at embryonic day 14 (E14) with 1 × 105 or 1 × 106 PFU of rMP-12 or RVax-1. Viral replication in maternal, placental, and fetal tissues was assessed at E18 in rats and at E17 or E19–21 in mice using viral RNA quantification and antigen detection. Fetal outcomes, including litter size, placental histopathology, and fetal demise, were recorded.
In rats, both vaccines showed minimal replication in placental and fetal tissues, indicating limited vertical transmission. In contrast, mice were more susceptible: viral RNA and antigens were detected in maternal livers, placentas, and fetal compartments. rMP-12–vaccinated mice showed reduced litter sizes and autolyzed placental tissues, whereas RVax-1–vaccinated mice exhibited fetal demise, with viral antigens detected in spongiotrophoblasts, syncytiotrophoblasts, and trophoblast giant cells of the junctional and labyrinth zones.
RVFV vaccines rMP-12 and RVax-1 exhibit residual placental tropism in mice but minimal replication in rats, highlighting species-specific differences. Mouse models may be useful for studying placental tropism, and these findings inform future optimization of vaccine safety during pregnancy.
•RVFV vaccines rMP-12 and RVax-1 showed minimal placental replication in rats.•Both vaccines replicated in mouse placentas, causing fetal demise in some cases.•Mouse model may be useful to study placental tropism of RVFV vaccines.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Animals
/ Antibodies, Viral - immunology
/ Antigens
/ Cattle
/ Cloning
/ Female
/ Fetuses
/ Fever
/ Genomes
/ Infectious Disease Transmission, Vertical - prevention & control
/ Mice
/ Mutation
/ Placenta
/ Proteins
/ Rats
/ Rift Valley Fever - immunology
/ Rift Valley Fever - prevention & control
/ Rift Valley fever virus - immunology
/ Rodents
/ Sheep
/ Tropism
/ Vaccines
/ Vertical transmission (disease)
/ Viral Vaccines - administration & dosage
/ Viruses
